TCGA-K4-A5RI-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.69513798
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.550
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- G2M_CHECKPOINT+0.470
- PROTEIN_SECRETION+0.380
- MYC_TARGETS_V2+0.360
- DNA_REPAIR+0.350
- MTORC1_SIGNALING+0.350
- ANDROGEN_RESPONSE+0.320
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.280
- TNFA_SIGNALING_VIA_NFKB-0.240
- INFLAMMATORY_RESPONSE-0.230
- ALLOGRAFT_REJECTION-0.210
- INTERFERON_ALPHA_RESPONSE-0.200
- HEDGEHOG_SIGNALING-0.190
- INTERFERON_GAMMA_RESPONSE-0.170
- KRAS_SIGNALING_DN-0.160
- ANGIOGENESIS-0.140
- IL2_STAT5_SIGNALING-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.822 |
| 2 | TCGA-94-7557-01A-11R-2125-07 | — | cohortMD1 | 0.821 |
| 3 | SJEPD031129_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.796 |
| 4 | MDT-AP-0322 | Med | Medulloblastoma | 0.791 |
| 5 | R122 | — | — | 0.789 |
| 6 | SRR12696742 | — | — | 0.788 |
| 7 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.787 |
| 8 | SRR23303771 | — | — | 0.787 |
| 9 | beb52b13-584a-4227-abe8-9861c3388c14 | — | — | 0.785 |
| 10 | TCGA-21-1071-01A-01R-0692-07 | — | cohortSQ2 | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |